

COMPANY RESULTS

China Sunshine Chemical (CSSC SP)

2H22: Results In Line With Expectations; Stronger Performance Forecast

Sunsine recorded 2H22 net profit of Rmb214.9m (-10.9% yoy), taking 2022 core profit to Rmb606.3m (+11.8% yoy), largely in line with our forecast. The lower 2H22 revenue was driven by a decline in sales volume and ASPs. While we have raised earnings expectations for 2023-24 due to capacity expansion projects, we also accounted for an expected decline in crude oil price by the US EIA. Maintain BUY with a 28% higher target price of S\$0.575.

2022 RESULTS

Year to 31 Dec (Rmbm)	2H22	2H21	yoy % chg	2022	2021	yoy % chg
Revenue	1,802.5	1,967.7	(8.4)	3,825.0	3,725.2	2.7
Gross profit	469.9	494.2	(4.9)	1,163.9	1,046.5	11.2
Gross margin (%)	26.1	25.1	+1.0ppt	30.4	28.1	+2.3ppt
Net profit	214.9	241.1	(10.9)	642.4	506.3	26.9
Net margin (%)	11.9	12.3	(0.3ppt)	16.8	13.6	+3.2ppt
Net profit (adjusted)	214.9	241.1	(10.9)	606.3	542.4	11.8
Net margin (adjusted) (%)	11.9	12.3	(0.3ppt)	15.9	14.6	+1.3ppt

Source: Sunsine, UOB Kay Hian

RESULTS

- Results in line with expectations.** China Sunshine Chemical's (Sunsine) 2H22 net profit fell by 11% yoy to Rmb214.9m, bringing 2022 core profit to 95% of our full-year estimates. 2H22 performance came on the back of lower revenue of Rmb1,802.5m (-8.4% yoy) due to both a decline in sales volume to 95,731 tonnes (-6.4% yoy) and a 2% yoy decrease in ASPs of rubber accelerators to Rmb18,532/tonne. For 2022, overall ASP increased by 8% yoy to Rmb20,237/tonne, as Sunsine was able to pass on the increase in raw material prices to customers. This drove the 2.7% yoy rise in 2022 revenue, offset by the 5% lower sales volume. 2022 core profit of Rmb606.3m (+11.8% yoy) excludes an Rmb36.1m tax refund received in 1H22 for the overpayment of 2021 tax expenses.
- Higher margins recorded; special dividend proposed.** Due to lower recorded revenue, gross profit fell by 4.9% yoy to Rmb469.9m in 2H22. However, 2H22 gross margin expanded 1.0ppt yoy to 26.1% (2H21: 25.1%, 1H22: 34.3%), with a more favourable sales mix comprising a higher proportion of antioxidant products. Full-year gross and core profit margins also improved by 2.3ppt yoy to 30.4% and by 1.3ppt yoy to 15.9% respectively. Management has proposed to pay out S\$0.025/share, consisting of a final DPS of S\$0.01/share and a special DPS of S\$0.015/share (2021: S\$0.01/share).

KEY FINANCIALS

Year to 31 Dec (Rmbm)	2021	2022	2023F	2024F	2025F
Net turnover	3,725	3,825	3,696	4,211	4,284
EBITDA	829	897	784	897	918
Operating profit	699	734	613	719	733
Net profit (rep./act.)	506	642	491	575	586
Net profit (adj.)	542	606	491	575	586
EPS (Fen)	55.9	62.8	50.8	59.6	60.7
PE (x)	4.3	3.8	4.7	4.0	4.0
P/B (x)	0.7	0.6	0.6	0.5	0.5
EV/EBITDA (x)	1.0	0.9	1.1	0.9	0.9
Dividend yield (%)	4.2	5.1	4.0	4.6	5.0
Net margin (%)	13.6	16.8	13.3	13.7	13.7
Net debt/(cash) to equity (%)	(43.4)	(37.0)	(36.9)	(32.8)	(37.2)
Interest cover (x)	n.a.	n.a.	n.a.	n.a.	n.a.
ROE (%)	17.2	18.7	12.7	13.6	12.5
Consensus net profit	-	-	485	542	565
UOBKH/Consensus (x)	-	-	1.01	1.06	1.04

Source: Sunsine, Bloomberg, UOB Kay Hian

BUY

(Maintained)

Share Price	S\$ 0.465
Target Price	S\$ 0.575
Upside	+23.7%
(Previous TP:	S\$ 0.45)

COMPANY DESCRIPTION

Sunsine produces rubber chemicals, primarily rubber accelerators and other related rubber chemicals such as anti-scorching agents.

STOCK DATA

GICS sector	Materials
Bloomberg ticker:	CSSC SP
Shares issued (m):	965.3
Market cap (S\$ m):	448.9
Market cap (US\$m):	337.6
3-mth avg daily t'over (US\$m):	0.0

Price Performance (%)

52-week high/low S\$ 0.490/S\$ 0.395


1mth	3mth	6mth	1yr	YTD
2.2	10.7	5.7	2.1	9.4

Major Shareholders

	%
Xu Cheng Qiu	61.1

FY23 NAV/Share (Rmb)	4.15
FY23 Net Cash/Share (Rmb)	1.53

PRICE CHART



Source: Bloomberg

ANALYST(S)

Heidi Mo
+65 6590 6630
heidimo@uobkayhian.com

John Cheong
+65 6590 6623
johncheong@uobkayhian.com

- **Continuous expansion projects undertaken.** In Oct 22, Sunsine commenced the construction of a project with a 20,000 tonnes/year capacity for an intermediate material used to produce many kinds of accelerators. Construction of Phase 2 of an insoluble sulphur project will also increase insoluble sulphur capacity by 50% to 90,000 tonnes/year. These projects are expected to be completed by end-23, and are likely to lift sales volume when operational.

STOCK IMPACT

- **Strong balance sheet and healthy cash flow.** As of end-22, total cash and bank balances stood at Rmb1,364.9m with no debt outstanding, which equates to Rmb1.41/share (S\$0.27/share). Additionally, free cash flow generated in 2022 remained positive at Rmb122m (2021: Rmb163m) despite capacity expansion efforts. Correspondingly, net cash per share is estimated to increase from Rmb0.86/share (S\$0.16/share) to Rmb1.06/share (S\$0.20/share) and Rmb1.21/share (S\$0.23/share) in 2023 and 2024 respectively.

EARNINGS REVISION/RISK

- Due to lower expectations for crude oil price according to US Energy Information Administration (EIA), we have tweaked our 2023 and 2024 gross margin assumptions from 30.0% to 29.0% and 30.0% to 29.1% respectively.
- We have also raised 2023/24 earnings estimates by 6%/7% to Rmb491m/Rmb575m respectively, on account of an improved outlook for automobile sales in China, which is expected to grow at 4% yoy in 2023.

VALUATION/RECOMMENDATION

- **Maintain BUY with a 28% higher target price of S\$0.575 (from S\$0.45)**, pegged to a multiple of 5.9x 2023F PE, its long-term average mean. Previously, we valued Sunsine based on 4.9x (-0.5SD below mean) 2023F PE, in line with its historical five-year average. We have raised our valuation multiple due to a less challenging outlook with China's reopening.

SHARE PRICE CATALYST


- China's reopening leading to higher consumption.
- Production commencement for new capacities.

PEER COMPARISON

Company	Ticker	Trading Curr (lcy)	Price @ 29-Mar-23 (lcy)	Market Cap (US\$m)	PE		P/B		EV/EBITDA		ROE 2023 (%)	Yield 2023 (%)	Net Gearing (%)
					2023 (x)	2024 (x)	2023 (x)	2024 (x)	2023 (x)	2024 (x)			
China Sunsine	CSSC SP	S\$	0.465	338	5.0	4.4	0.6	0.5	1.3	1.1	12.0	3.8	(37.0)
Shandong Yanggu Huatai	300121 CH	CNY	11.18	657	6.8	5.5	1.4	1.1	4.7	3.6	21.0	4.5	(3.0)
Lanxess AG	LXS GR	EUR	36.58	3,423	11.1	8.1	0.6	0.6	7.6	6.7	8.7	3.0	86.8
Eastman Chemical	EMN US	USD	81.74	9,738	10.5	9.2	1.7	1.6	8.1	7.5	15.9	3.9	92.7
Arkema SA	AKE FP	EUR	88.4	7,190	9.9	8.3	0.9	0.8	5.5	5.2	9.3	3.8	22.1
Global average					9.6	7.8	1.2	1.0	6.5	5.7	13.7	3.8	49.7


Source: Bloomberg, UOB Kay Hian

ASP FOR RUBBER ACCELERATORS (RA)



Source: China Sunsine, UOB Kay Hian

ASP FOR ANILINE



Source: China Sunsine, UOB Kay Hian

PROFIT & LOSS

Year to 31 Dec (Rmbm)	2022	2023F	2024F	2025F
Net turnover	3,825.0	3,696.5	4,210.7	4,284.5
EBITDA	897.1	783.5	896.7	917.9
Deprec. & amort.	163.4	170.3	177.9	185.0
EBIT	733.7	613.2	718.8	732.9
Associate contributions	0.0	0.0	0.0	0.0
Net interest income/(expense)	0.0	0.0	0.0	0.0
Pre-tax profit	733.7	613.2	718.8	732.9
Tax	(91.3)	(122.6)	(143.8)	(146.6)
Minorities	0.0	0.0	0.0	0.0
Net profit	642.4	490.5	575.1	586.3
Net profit (adj.)	606.3	490.5	575.1	586.3

BALANCE SHEET

Year to 31 Dec (Rmbm)	2022	2023F	2024F	2025F
Fixed assets	861.7	780.1	691.4	595.6
Other LT assets	213.0	209.3	205.1	200.9
Cash/ST investment	1,364.9	1,479.8	1,463.5	1,829.6
Other current assets	1,784.9	1,996.1	2,400.1	2,570.7
Total assets	4,224.5	4,465.3	4,760.1	5,196.9
ST debt	0.0	0.0	0.0	0.0
Other current liabilities	532.7	458.1	296.4	279.0
LT debt	0.0	0.0	0.0	0.0
Other LT liabilities	0.0	0.0	0.0	0.0
Shareholders' equity	3,691.8	4,007.2	4,463.7	4,917.9
Minority interest	0.0	0.0	0.0	0.0
Total liabilities & equity	4,224.5	4,465.3	4,760.1	5,196.9

CASH FLOW

Year to 31 Dec (Rmbm)	2022	2023F	2024F	2025F
Operating	207.5	371.4	183.0	579.0
Pre-tax profit	733.7	613.2	718.8	732.9
Tax	(53.6)	(72.1)	(109.7)	(142.1)
Deprec. & amort.	159.6	166.6	173.7	180.7
Working capital changes	(631.5)	(336.3)	(599.8)	(192.5)
Non-cash items	(0.7)	0.0	0.0	0.0
Investing	(141.0)	(81.3)	(80.8)	(80.7)
Capex (growth)	(85.2)	(85.0)	(85.0)	(85.0)
Proceeds from sale of assets	0.1	0.0	0.0	0.0
Others	(55.9)	3.7	4.2	4.3
Financing	(121.5)	(175.2)	(118.6)	(132.2)
Dividend payments	(123.1)	(175.2)	(118.6)	(132.2)
Issue of shares	0.0	0.0	0.0	0.0
Loan repayment	0.0	0.0	0.0	0.0
Others/interest paid	1.6	0.0	0.0	0.0
Net cash inflow (outflow)	(55.0)	114.9	(16.3)	366.1
Beginning cash & cash equivalent	1,377.3	1,364.9	1,479.8	1,463.5
Changes due to forex impact	42.6	0.0	0.0	0.0
Ending cash & cash equivalent	1,364.9	1,479.8	1,463.5	1,829.6

KEY METRICS

Year to 31 Dec (%)	2022	2023F	2024F	2025F
Profitability				
EBITDA margin	23.5	21.2	21.3	21.4
Pre-tax margin	19.2	16.6	17.1	17.1
Net margin	16.8	13.3	13.7	13.7
ROA	15.8	11.3	12.5	11.8
ROE	18.7	12.7	13.6	12.5
Growth				
Turnover	2.7	(3.4)	13.9	1.8
EBITDA	8.2	(12.7)	14.4	2.4
Pre-tax profit	4.9	(16.4)	17.2	2.0
Net profit	26.9	(23.6)	17.2	2.0
Net profit (adj.)	11.8	(19.1)	17.2	2.0
EPS	12.3	(19.1)	17.2	2.0
Leverage				
Debt to total capital	0.0	0.0	0.0	0.0
Debt to equity	0.0	0.0	0.0	0.0
Net debt/(cash) to equity	(37.0)	(36.9)	(32.8)	(37.2)
Interest cover (x)	n.a.	n.a.	n.a.	n.a.

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2023, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W